Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05853972.7Aexternal-prioritypatent/EP1827483B1/en
Application filed by Swedish Orphan Biovitrum Ab (Publ)filedCriticalSwedish Orphan Biovitrum Ab (Publ)
Publication of CY1115607T1publicationCriticalpatent/CY1115607T1/en
Η παρούσα εφεύρεση παρέχει μακροχρόνιες σταθερές φαρμακοτεχνικές μορφές λυοφιλοποιημένου τελεστή αύξησης κερατινοκυττάρων και μεθόδους παρασκευής λυοφιλοποιημένης σύνθεσης που να περιλαμβάνει τελεστή αύξησης κερατινοκυττάρων.The present invention provides long-term stable formulations of a lyophilized keratinocyte growth factor and methods of preparing a lyophilized composition comprising a keratinocyte growth factor.
CY20141100787T2004-12-152014-09-26
THERAPEUTIC PHARMACEUTICAL FORMS FOR CERTAIN CELL GROWTH
CY1115607T1
(en)
fostamatinib or a pharmaceutically acceptable salt of fostamatinib, or a hydrate, solvate or N-oxide of fostamatinib or the pharmaceutically acceptable salt of fostamatinib, in particular fostamatinib disodium, optionally in the form of a hydrate